Carol
Diagnosed with
MM 6 years ago
Hypothetical patient
Carol, 78 years old
Meet Carol, a triple-class–exposed patient who has received 4 lines of treatment and is considering TALVEY® for her fifth line of treatment.
Biography
- Lives in a rural area with a spouse in good health; does not have children
- Retired, relatively active, works around her house on a daily basis
Key considerations
- Clinical concern for cytopenia and infection
Labs, imaging, and presentation
- M-protein (lgG kappa): Best (during 4L)=0.2 g/dL; current=1.4 g/dL (up from 0.2 g/dL in 2 months)
- ANC: 1.5 × 103/mL
- Hgb: 10.6 g/dL
- lgG levels: 450 g/L
- FISH: t(4;14)
- ECOG PS: 1
- Has begun experiencing increased fatigue and muscle weakness
Carol's treatment journey since being diagnosed in 2019
Carol is triple-class exposed and has become refractory to her fourth line of treatment.
4L
DPd
Powerful efficacy for appropriate patients like Carol
In T-cell redirection–naïve patients receiving TALVEY® Q2W, ORR was 73.6% (n=65/87) (95% Cl, 63.0%–82.4%).1
- mDOR: NE
- mTTR: 1.3 months (range: 0.2–9.2 months)
- mFU: 5.9 months (range: 0–9.5 months)
Carol was prescribed TALVEY® with Q2W dosing.
Robert
Diagnosed with
MM 10 years ago
Hypothetical patient
Robert, 68 years old
Meet Robert, a triple-class–exposed patient who has received 4 lines of treatment and is considering TALVEY® for his fifth line of treatment.
Biography
- Married with 3 adult children
- Lives in a suburban area and works as an accountant
- Exercises daily, either riding his bicycle or hiking
- History of mild hypertension
Key considerations
- Received a stem cell transplant
Labs, imaging, and presentation
- M-protein (lgG kappa): Best (during 4L)=0 g/dL; current=1.5 g/dL (increased from 0 g/dL in 3 months—he responded to his 4L regimen for approximately 1 year)
- Bone lesions: Lytic lesion in the right hip
- FISH: Standard risk
- ECOG PS: 0
- Reports bone pain in his right hip
Robert's treatment journey since being diagnosed in 2015
Robert is triple-class exposed and has become refractory to his fourth line of treatment.
BCMA product
Powerful efficacy for appropriate patients like Robert
In T-cell redirection–exposed patients receiving TALVEY® QW, ORR was 72% (n=23/32) (95% Cl, 53%–86%).1
- An estimated 59% of responders maintained response for at least 9 months
- mFU: 10.4 months
Robert was prescribed TALVEY® with QW dosing.
ANC, absolute neutrophil count; BCMA, B-cell maturation antigen; CI, confidence interval; DPd, daratumumab, pomalidomide, and dexamethasone; ECOG PS, Eastern
Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; Hgb, hemoglobin; IgG, immunoglobulin G; mDOR, median duration of response;
mFU, median follow-up; MM, multiple myeloma; mTTR, median time to response; NE, not estimable; ORR, overall response rate; QW, once weekly; Q2W, every 2 weeks.
- TALVEY® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.